Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1573214 | 0.82 | SMN1; SMN2 (0.46) | GAATHRBSMN1; SMN2JAK2JAK1 | |
| SCHEMBL8303730 | 0.81 | KDM4E (0.45) | NAMPTRORCGPR119KDM4EPKM | |
| SCHEMBL8302357 | 0.81 | KDM4E (0.45) | NAMPTRORCGPR119KDM4EPKM | |
| SCHEMBL27160438 | 0.81 | RORC (0.46) | JAK2JAK1STSNAMPTRORC | |
| SCHEMBL27160443 | 0.81 | RORC (0.46) | JAK2JAK1STSNAMPTRORC | |
| SCHEMBL7665078 | 0.81 | MAPK1 (0.56) | — | |
| SCHEMBL8263390 | 0.80 | STS (0.50) | GAATHRBSMN1; SMN2JAK2JAK1 | |
| SCHEMBL5509395 | 0.80 | STS (0.50) | GAATHRBSMN1; SMN2JAK2JAK1 | |
| SCHEMBL19358613 | 0.80 | STS (0.50) | GAATHRBSMN1; SMN2JAK2JAK1 | |
| SCHEMBL19358614 | 0.80 | STS (0.50) | GAATHRBSMN1; SMN2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082426-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-06-27 | — | — | US | disclosed |
| EP-1086083-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-1086083-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064399-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082426-A1 | Protease inhibitors | CTSK, CTSZ, CTSB | GAA 123/4885THRB 4516/4885SMN1; SMN2 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.